Dr. Amara Sarwal, MD

Dr. Sarwal practices at Castleview Hospital in Price, Utah, part of Lifepoint Health.

Dr. Sarwal's NPI, 1962998948, was assigned on July 2, 2018. Dr. Sarwal holds Utah license 12264175-1205.

Dr. Sarwal's primary practice is Castleview Hospital, at 300 North Hospital Drive, Price, UT 84501 in Carbon County. The practice phone is (435) 637-4800.

Dr. Sarwal's primary practice is Castleview Hospital in Price, Utah, part of Lifepoint Health. Dr. Sarwal is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Sarwal to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sarwal practices, 6 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Sarwal's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Sarwal is licensed in Utah.

CMS data shows 135 Medicare services from Dr. Sarwal across 2 procedure codes in 2024, for 71 Medicare patients. Medicare paid $5,129 for them.

CMS counts 71 Medicare patients who saw Dr. Sarwal in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. Their average risk score is 3.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sarwal's median patient age at 74, with 52% women.

In 2024, Dr. Sarwal wrote 255 Medicare Part D claims for 56 patients. 88% of them were for generic drugs. CMS names the drug for 189 of them, across 9 drugs with 11 or more claims each, at $1,700 in total drug cost. In 2023, CMS named 96 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Sarwal for performance year 2024, reported as part of a group. Dr. Sarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sarwal as offering telehealth.

Dmand AI links 22 papers to Dr. Sarwal, published from 2019 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Acute Kidney Injury, Hypoglycemic Agents and Metformin. Dr. Sarwal has published most often in Am J Med Sci. Dr. Sarwal's most frequent co-authors are Srinivasan Beddhu, MD, Susan Kim, MD and Glenn Matthew Chertow, MD.

CMS Open Payments shows 1 general payment to Dr. Sarwal from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. Novo Nordisk Inc paid the most, $88.